Susan Vermeir
VP, Pharmaceutical Regulatory Affairs at ALX Oncology - Burlingame, California, United States
Susan Vermeir's Colleagues at ALX Oncology
Susan Vermeir's Contact Details
["(353) 161-8000"]
ALX Oncology
Susan Vermeir's Company Details
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.